Edison Baldwin May 5, 2021
Teva Pharmaceutical Industries Limited [NYSE: TEVA] loss -1.06% or -0.11 points to close at $10.25 with a heavy trading volume of 7004076 shares. The company report on June 28, 2021 that Teva and Bioeq Announce Commercial Partnership for Biosimilar.
Agreement includes commercializing biosimilar candidate of ophthalmology drug ranibizumab (Lucentis®) in Europe, Canada, Israel and global markets.
Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Bioeq AG (“Bioeq”) announced that they have entered into a strategic partnership for the exclusive commercialization of Bioeq’s FYB201, a biosimilar candidate to Lucentis® (ranibizumab) in Europe, Canada, Israel and New Zealand.
It opened the trading session at $10.42, the shares rose to $10.46 and dropped to $10.185, the range by which the price of stock traded the whole day. The daily chart for TEVA points out that the company has recorded 4.27% gains over the past six months. H